Published Research and Presentations

Adding Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasivebladder cancer: a randomised phase 3 trial: The BCG+MM Trial (ANZUP 1301)

BCG+MM

EAU 23

10/03/2023

Hayne D., Stockler M., Martin A.J., Mccombie S., Zebic D., Krieger L., Anderson P., Bastick P., Beardsley E., Blatt A., Frydenberg M., Green W., Grummet J., Hawks C., Ischia J., Mitterdorfer A., Patel M., Roberts M., Sengupta S., Srivastav R., Winter M., Redfern A.D., Davis I.D.

EVOLUTION: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (ANZUP 2001

EVOLUTION

22/02/2023

Shahneen Sandhu, Shalini Subramaniam Michaels. Kolman. Marfin R. Stockler, Andrew James Martin. Izabella Pokorski Jeffrey C Goh. David A. Pallison. Nattakom Ohiantravan• Craig Gedye Natalie K. Ruthefford Anthony M. Joshua Thean Hsiang Tan'. Ian o. Kirkwood'. Sze Ting Lee, Andrew J. Weickhardt, Ramin Alipaur1, Andrew Nguyen, Ian Davis, Louise Emmett,

Abstract 372: Societal benefits of surrogate outcomes to support reimbursement decisions: the case of prostate cancer

Other

22/02/2023

Rafael Emilio de Feria Cardet, Stephen Goodall, Tracey-Lea Laba, Marion Haas, Ian D. Davis, Richard De Abreu Lourenço.

Abstract #394646: Trial in Progress – Primary retroperitoneal lymph node dissection for clinical stage II testicular germ cell tumour and its impact on health-related quality of life compared to chemotherapy or radiotherapy (PRESTIGE)

Other

22/02/2023

Ciara Conduit, Jeremy Lewin, Elizabeth C Liow, Haryana Dhillon, Wei Hong, Richard De Abreu Lourenco, Nathan Lawrentschuk, Benjamin Thomas, Peter Grimison, Shomik Sengupta, Ben Tran

Abstract #393644: Trial in Progress – Exploring the activity of pseudoephedrine in treating retrograde ejaculation following RPLND in survivors of testicular cancer (PREPARE)

Other

22/02/2023

Ciara Conduit, Jeremy Lewin, Ie-Wen Sim, Haryana Dhillon, Wei Hong, Amanda Hutchinson, Gulfam Ahmad, Nathan Lawrentschuk, Benjamin Thomas, Matt Leonard, Ben Tran

An international r andomi z ed phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP protocol 1302)

P3BEP

22/02/2023

DZebic, M Stockler A Martin F Pashankar, B Tran D Mazhar, R Huddart, M Wheater, E Walpole, E Dunwoodie, DR Feldman, A Birtle AG Stevanovic, D Wyld, FJ Hanning, P SGrimison

DASL-HiCaP: Darolutamide Augments Standard therapy for Localized very High-risk Cancer of the Prostate – a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801

DASL-HiCaP

22/02/2023

T Niazi SM McBride, S Williams, ID Davis, MR Stockler AJ Martin, HT Chung, FT Roncolato, A Ebacher, E Khoo, J Martin, TS Lim, S Hughes, D Pryor, J Catto, P Kelly, LG Rezaei, SC Morgan, R Rendon, CJ Sweeney

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP ANZUP 1603): a biomarker analysis from a randomised, open-label, phase 2 trial

TheraP

EANM’22 Annual Congress

31/10/2022

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman

PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER ANALYSIS OF SAFETY AND EFFICACY OF THE PCR-MIB PHASE II CLINICAL TRIAL (ANZUP 1502)

PCR MIB

ESMO

13/09/2022

A. Weickhardt, F. Foroudi, N. Lawrentschuk, Jing Xie, Komal Konijia, Mark Sidhom, Abhijit Pal, P. Grimison, A. Zhang, S. Ng, C. Tang, E. Hovey, C. Chen, G. Hruby, A. Guminski, M. McJannett, C. Conduit, B. Tran,I.D Davis, D. Hayne, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group(ANZUP)

P3 BEP: Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (ANZUP protocol 1302)

P3BEP

MOGA 2022

19/08/2022

D Zebic, M Stockler, A Martin, F Pashankar, B Tran, D Mazhar, R Huddart, M Wheater, E Walpole, E Dunwoodie, D Feldman, A Birtle, AG Stevanovic, D Wyld, FJ Hanning, PS Grimison, Australian and New Zealand Urogenital and Prostate Cancer Trials Group